Showing results (141-150 of 193) with videos related to

Sort By:
Pageof 20
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 6, 2016
Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical ResultsBerthold A Nock, Aikaterini Kaloudi, Emmanouil Lymperis, et al.
Seminars in Nuclear Medicine|March 31, 2010
Preclinical and clinical studies of peptide receptor radionuclide therapyStefan E Pool, Eric P Krenning, Gerben A Koning, et al.
International Journal of Cancer|May 12, 2019
Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu-DOTAGA-PEG2 -RM26Bogdan Mitran, Sara S Rinne, Mark W Konijnenberg, et al.
Molecular Imaging and Biology|March 21, 2018
In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate CancerIngrid L Bakker, Sandra T van Tiel, Joost Haeck, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 19, 2018
Translational molecular imaging in exocrine pancreatic cancerBart Cornelissen, James C Knight, Somnath Mukherjee, et al.
Arthritis Research & Therapy|January 30, 2014
Increased physical activity severely induces osteoarthritic changes in knee joints with papain induced sulfate-glycosaminoglycan depleted cartilageMichiel Siebelt, Harald C Groen, Stuart J Koelewijn, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 6, 2004
Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotideMarion De Jong, Roelf Valkema, Arthur Van Gameren, et al.
Journal of Medicinal Chemistry|February 23, 2013
Gastrin releasing peptide receptor-directed radioligands based on a bombesin antagonist: synthesis, (111)in-labeling, and preclinical profilePanteleimon J Marsouvanidis, Berthold A Nock, Bouchra Hajjaj, et al.
Pageof 20